Rheumatic Heart Disease Global Market Report 2025

Description

Rheumatic heart disease (RHD) is a chronic condition caused by permanent damage to the heart valves due to rheumatic fever, an inflammatory disease that results from untreated or inadequately treated streptococcal throat infections. The immune response triggered by the infection causes inflammation and scarring of the heart valves, impairing their function and potentially leading to heart failure, arrhythmias, or other complications.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary types of rheumatic heart disease include valve-related disease, myocarditis, and pericarditis. Valve-related rheumatic heart disease occurs when rheumatic fever damages the heart valves, leading to impaired blood flow and complications such as stenosis or regurgitation. Affected age groups include pediatric, adolescent, adult, and geriatric populations. Rheumatic heart disease is treated and managed across various healthcare settings, such as hospitals, diagnostic centers, and research institutions. The distribution channels for related medications include hospital pharmacies, retail pharmacies, online pharmacies, and direct sales.

The rheumatic heart disease market research report is one of a series of new reports from The Business Research Company that provides rheumatic heart disease market statistics, including the rheumatic heart disease industry global market size, regional shares, competitors with the rheumatic heart disease market share, detailed rheumatic heart disease market segments, market trends, and opportunities, and any further data you may need to thrive in the rheumatic heart disease industry. This rheumatic heart disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The rheumatic heart disease market size has grown strongly in recent years. It will grow from$2.56 billion in 2024 to $2.72 billion in 2025 at a compound annual growth rate (CAGR) of 6.3%. The growth during the historic period can be attributed to the prevalence of untreated strep infections, limited access to healthcare in low-income regions, a lack of awareness about rheumatic heart disease, delayed diagnosis and treatment, and insufficient vaccination programs.

The rheumatic heart disease market size is expected to see strong growth in the next few years. It will grow to$3.44 billion in 2029 at a compound annual growth rate (CAGR) of 6.0%. The growth during the forecast period can be attributed to the increasing adoption of preventive screening programs, growing awareness about early detection, rising healthcare investments in developing regions, the expansion of telemedicine for remote diagnosis, and government initiatives for disease prevention. Key trends anticipated in the forecast period include the growing use of AI in diagnostics, the expansion of echocardiography-based screening, the integration of mobile health solutions, the development of novel anti-inflammatory therapies, and collaborations aimed at global disease eradication.

The growing prevalence of strep throat is expected to drive the growth of the rheumatic heart disease market in the future. Strep throat is a bacterial infection caused by Streptococcus pyogenes (group A streptococcus), leading to throat inflammation, pain, fever, swollen lymph nodes, and difficulty swallowing. The rise in antibiotic resistance is making streptococcal infections harder to treat effectively, resulting in prolonged illnesses and higher transmission rates in communities. Rheumatic heart disease develops as a long-term complication of untreated or recurrent strep throat infections, emphasizing the importance of early diagnosis and treatment of streptococcal infections to prevent severe heart damage. For example, in April 2023, the Centers for Disease Control and Prevention (CDC), a US-based government agency, reported that strep throat accounts for approximately 5.2 million outpatient visits annually among individuals under 65 years old. These visits lead to 2.8 million antibiotic prescriptions each year. Therefore, the increasing prevalence of strep throat is contributing to the growth of the rheumatic heart disease market.

Key players in the rheumatic heart disease market are adopting strategic partnerships to develop innovative treatments and diagnostic solutions. These partnerships combine resources and expertise to advance research, improve diagnostic and therapeutic technologies, expand market reach, and expedite commercialization. For instance, in July 2023, the World Heart Federation (WHF), a Switzerland-based NGO, joined forces with the Philips Foundation, a Netherlands-based nonprofit, to increase awareness, medical training, and early detection of rheumatic heart disease (RHD) in the Asia-Pacific (APAC) region. Launched in the Philippines, this initiative aims to improve healthcare access for over half a million Filipino children at risk by equipping healthcare facilities with trained professionals and advanced diagnostic tools. This collaboration highlights a shared commitment to strengthening healthcare infrastructure and ensuring timely intervention for RHD patients.

In February 2025, Light AI Inc., a healthcare technology company based in Canada, partnered with MrBeast Industries to support global health initiatives. The collaboration focuses on providing AI-powered Strep A tests across Africa, enabling early detection and prevention of the disease to reduce the risk of complications such as rheumatic heart disease. MrBeast Industries is a US-based media and entertainment company known for its digital content creation.

Major players in the rheumatic heart disease market are Pfizer Inc., Merck & Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Novartis AG, Abbott Laboratories, GlaxoSmithKline plc (GSK), Medtronic plc, Siemens Healthineers AG, Fresenius Medical Care AG & Co. KGaA, Becton Dickinson and Company (BD), GE HealthCare Technologies Inc., Mayo Clinic, Boston Scientific Corporation, Johns Hopkins Medicine, Terumo Corporation, The Mount Sinai Health System Inc., Apollo Hospitals Enterprise Limited, Fortis Healthcare Limited, and Medanta.

North America was the largest region in the rheumatic heart disease market in 2024. The regions covered in rheumatic heart disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the rheumatic heart disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The rheumatic heart disease market consists of revenues earned by entities by providing services such as surgical treatments, diagnostic tests, preventive care services, and pediatric care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The rheumatic heart disease market also includes sales of antibiotics, anti-inflammatory medications, diuretics, beta-blockers, and ACE inhibitors. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Rheumatic Heart Disease Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on rheumatic heart disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for rheumatic heart disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The rheumatic heart disease market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Valve; Myocarditis; Pericarditis
2) By Age Group: Pediatric; Adolescent; Adult; Geriatric
3) By Application: Hospital; Diagnostic Centre; Research Centre
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Direct Sales
Subsegments:
1) By Valve: Mitral Valve Disease; Aortic Valve Disease; Tricuspid Valve Disease; Pulmonary Valve Disease
2) By Myocarditis: Acute Myocarditis; Chronic Myocarditis; Fulminant Myocarditis
3) By Pericarditis: Acute Pericarditis; Chronic Pericarditis; Constrictive Pericarditis; Effusive Pericarditis
Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Bayer AG; Sanofi S.A.; AstraZeneca plc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r34954

1. Executive Summary

2. Rheumatic Heart Disease Market Characteristics

3. Rheumatic Heart Disease Market Trends And Strategies

4. Rheumatic Heart Disease Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Rheumatic Heart Disease Growth Analysis And Strategic Analysis Framework

5.1. Global Rheumatic Heart Disease PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Rheumatic Heart Disease Market Growth Rate Analysis
5.4. Global Rheumatic Heart Disease Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Rheumatic Heart Disease Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Rheumatic Heart Disease Total Addressable Market (TAM)

6. Rheumatic Heart Disease Market Segmentation

6.1. Global Rheumatic Heart Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Valve
Myocarditis
Pericarditis
6.2. Global Rheumatic Heart Disease Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pediatric (0-14 Years)
Adolescent (15-24 Years)
Adult (25-64 Years)
Geriatric (65 Years And Above)
6.3. Global Rheumatic Heart Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital
Diagnostic Centre
Research Centre
6.4. Global Rheumatic Heart Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Direct Sales
6.5. Global Rheumatic Heart Disease Market, Sub-Segmentation Of Valve, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Mitral Valve Disease
Aortic Valve Disease
Tricuspid Valve Disease
Pulmonary Valve Disease
6.6. Global Rheumatic Heart Disease Market, Sub-Segmentation Of Myocarditis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Acute Myocarditis
Chronic Myocarditis
Fulminant Myocarditis
6.7. Global Rheumatic Heart Disease Market, Sub-Segmentation Of Pericarditis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Acute Pericarditis
Chronic Pericarditis
Constrictive Pericarditis
Effusive Pericarditis

7. Rheumatic Heart Disease Market Regional And Country Analysis

7.1. Global Rheumatic Heart Disease Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Rheumatic Heart Disease Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Rheumatic Heart Disease Market

8.1. Asia-Pacific Rheumatic Heart Disease Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Rheumatic Heart Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Rheumatic Heart Disease Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Rheumatic Heart Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Rheumatic Heart Disease Market

9.1. China Rheumatic Heart Disease Market Overview
9.2. China Rheumatic Heart Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Rheumatic Heart Disease Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Rheumatic Heart Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Rheumatic Heart Disease Market

10.1. India Rheumatic Heart Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Rheumatic Heart Disease Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Rheumatic Heart Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Rheumatic Heart Disease Market

11.1. Japan Rheumatic Heart Disease Market Overview
11.2. Japan Rheumatic Heart Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Rheumatic Heart Disease Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Rheumatic Heart Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Rheumatic Heart Disease Market

12.1. Australia Rheumatic Heart Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Rheumatic Heart Disease Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Rheumatic Heart Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Rheumatic Heart Disease Market

13.1. Indonesia Rheumatic Heart Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Rheumatic Heart Disease Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Rheumatic Heart Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Rheumatic Heart Disease Market

14.1. South Korea Rheumatic Heart Disease Market Overview
14.2. South Korea Rheumatic Heart Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Rheumatic Heart Disease Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Rheumatic Heart Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Rheumatic Heart Disease Market

15.1. Western Europe Rheumatic Heart Disease Market Overview
15.2. Western Europe Rheumatic Heart Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Rheumatic Heart Disease Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Rheumatic Heart Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Rheumatic Heart Disease Market

16.1. UK Rheumatic Heart Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Rheumatic Heart Disease Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Rheumatic Heart Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Rheumatic Heart Disease Market

17.1. Germany Rheumatic Heart Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Rheumatic Heart Disease Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Rheumatic Heart Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Rheumatic Heart Disease Market

18.1. France Rheumatic Heart Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Rheumatic Heart Disease Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Rheumatic Heart Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Rheumatic Heart Disease Market

19.1. Italy Rheumatic Heart Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Rheumatic Heart Disease Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Rheumatic Heart Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Rheumatic Heart Disease Market

20.1. Spain Rheumatic Heart Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Rheumatic Heart Disease Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Rheumatic Heart Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Rheumatic Heart Disease Market

21.1. Eastern Europe Rheumatic Heart Disease Market Overview
21.2. Eastern Europe Rheumatic Heart Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Rheumatic Heart Disease Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Rheumatic Heart Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Rheumatic Heart Disease Market

22.1. Russia Rheumatic Heart Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Rheumatic Heart Disease Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Rheumatic Heart Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Rheumatic Heart Disease Market

23.1. North America Rheumatic Heart Disease Market Overview
23.2. North America Rheumatic Heart Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Rheumatic Heart Disease Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Rheumatic Heart Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Rheumatic Heart Disease Market

24.1. USA Rheumatic Heart Disease Market Overview
24.2. USA Rheumatic Heart Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Rheumatic Heart Disease Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Rheumatic Heart Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Rheumatic Heart Disease Market

25.1. Canada Rheumatic Heart Disease Market Overview
25.2. Canada Rheumatic Heart Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Rheumatic Heart Disease Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Rheumatic Heart Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Rheumatic Heart Disease Market

26.1. South America Rheumatic Heart Disease Market Overview
26.2. South America Rheumatic Heart Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Rheumatic Heart Disease Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Rheumatic Heart Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Rheumatic Heart Disease Market

27.1. Brazil Rheumatic Heart Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Rheumatic Heart Disease Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Rheumatic Heart Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Rheumatic Heart Disease Market

28.1. Middle East Rheumatic Heart Disease Market Overview
28.2. Middle East Rheumatic Heart Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Rheumatic Heart Disease Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Rheumatic Heart Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Rheumatic Heart Disease Market

29.1. Africa Rheumatic Heart Disease Market Overview
29.2. Africa Rheumatic Heart Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Rheumatic Heart Disease Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Rheumatic Heart Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Rheumatic Heart Disease Market Competitive Landscape And Company Profiles

30.1. Rheumatic Heart Disease Market Competitive Landscape
30.2. Rheumatic Heart Disease Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

31. Rheumatic Heart Disease Market Other Major And Innovative Companies

31.1. Novartis AG
31.2. Abbott Laboratories
31.3. GlaxoSmithKline plc (GSK)
31.4. Medtronic plc
31.5. Siemens Healthineers AG
31.6. Fresenius Medical Care AG & Co. KGaA
31.7. Becton Dickinson and Company (BD)
31.8. GE HealthCare Technologies Inc.
31.9. Mayo Clinic
31.10. Boston Scientific Corporation
31.11. Johns Hopkins Medicine
31.12. Terumo Corporation
31.13. The Mount Sinai Health System Inc.
31.14. Apollo Hospitals Enterprise Limited
31.15. Fortis Healthcare Limited

32. Global Rheumatic Heart Disease Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Rheumatic Heart Disease Market

34. Recent Developments In The Rheumatic Heart Disease Market

35. Rheumatic Heart Disease Market High Potential Countries, Segments and Strategies

35.1 Rheumatic Heart Disease Market In 2029 - Countries Offering Most New Opportunities
35.2 Rheumatic Heart Disease Market In 2029 - Segments Offering Most New Opportunities
35.3 Rheumatic Heart Disease Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer
250617_r34954_Rheumatic_Heart_Disease_GMR_2025